Interplay between inflammation and degeneration: using inclusion body myositis to study "neuroinflammation".
Dalakas
Marinos C
MC
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use; D004660:Encephalitis / Q000276:immunology; D006801:Humans; D007155:Immunologic Factors / Q000494:pharmacology / Q000627:therapeutic use; D007167:Immunotherapy / Q000379:methods / Q000639:trends; D018836:Inflammation Mediators / Q000276:immunology / Q000378:metabolism; D018482:Muscle, Skeletal / Q000276:immunology; D018979:Myositis, Inclusion Body / Q000188:drug therapy / Q000276:immunology*; D009410:Nerve Degeneration / Q000276:immunology*; D019636:Neurodegenerative Diseases / Q000276:immunology*
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D007155:Immunologic Factors; D018836:Inflammation Mediators